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Many membrane proteins are cleaved at the 
plasma membrane to release soluble ectodomains, 
which  may  exert  different  biological  activities 
(Murphy, 2008). Membrane-bound growth fac-
tors and cytokines become systemically available 
upon shedding. Soluble receptors for growth fac-
tors and cytokines can be antagonists of the cog-
nate cytokines, as is the case for IL-1 and TNF 
(Müllberg et al., 2000). Alternatively, soluble re-
ceptors can be agonistic, i.e., together with their 
respective ligands they stimulate cells, which are 
otherwise unresponsive to the cytokine, as dem-
onstrated  for  IL-6  trans-signaling  (Rose-John   
et al., 2006). A disintegrin and metalloprotease 
(ADAM) 17 is an important sheddase involved in 
the  proteolysis  of  membrane  proteins  such  as 
TNF, IL-6R, L-selectin, and ligands of the epi-
dermal growth factor receptor (EGF-R; Peschon 
et al., 1998). ADAM17-deficient mice are not vi-
able. Interestingly, these mice were reminiscent 
of mice lacking TGF- (Peschon et al., 1998). 
Recently, conditional ADAM17 knockout ani-
mals have been generated (Horiuchi et al., 2007, 
2009). Although these studies confirmed that 
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The protease a disintegrin and metalloprotease (ADAM) 17 cleaves tumor necrosis factor 
(TNF), L-selectin, and epidermal growth factor receptor (EGF-R) ligands from the plasma 
membrane. ADAM17 is expressed in most tissues and is up-regulated during inflammation 
and cancer. ADAM17-deficient mice are not viable. Conditional ADAM17 knockout models 
demonstrated proinflammatory activities of ADAM17 in septic shock via shedding of TNF.  
We used a novel gene targeting strategy to generate mice with dramatically reduced 
ADAM17 levels in all tissues. The resulting mice called ADAM17ex/ex were viable, showed 
compromised shedding of ADAM17 substrates from the cell surface, and developed eye, 
heart, and skin defects as a consequence of impaired EGF-R signaling caused by failure of 
shedding of EGF-R ligands. Unexpectedly, although the intestine of unchallenged homozygous 
ADAM17ex/ex mice was normal, ADAM17ex/ex mice showed substantially increased susceptibil-
ity to inflammation in dextran sulfate sodium colitis. This was a result of impaired shedding 
of EGF-R ligands resulting in failure to phosphorylate STAT3 via the EGF-R and, consequently, 
in defective regeneration of epithelial cells and breakdown of the intestinal barrier. Besides 
regulating the systemic availability of the proinflammatory cytokine TNF, our results demon-
strate that ADAM17 is needed for vital regenerative activities during the immune response. 
Thus, our mouse model will help investigate ADAM17 as a potential drug target.
© 2010 Chalaris et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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developed eye, hair, and skin defects 
reminiscent of mice lacking TGF-. 
Although the intestine of the homo-
zygous ADAM17ex/ex mice showed 
no overt abnormalities, the animals 
displayed dramatically increased sus-
ceptibility to intestinal inflammation 
induced by dextran sulfate sodium 
(DSS) as a consequence of impaired 
EGF-R–dependent regeneration caused by failure of shed-
ding of EGF-R ligands. Results show that during inflam-
mation,  ADAM17  is  not  only  involved  in  shedding  the 
proinflammatory cytokine TNF but also in the regulation of 
regenerative responses. Thus, our mouse model will help   
investigate ADAM17 as a potential drug target in TNF- 
and/or  EGF-R–dependent  pathologies  in  inflammation 
and cancer.
RESULTS AND DISCUSSION
To construct a targeting vector for the ADAM17 gene, we in-
serted a loxP sequence followed by a noncanonical donor 
splice site downstream of a cryptic acceptor splice site within 
intron11. This manipulation generated a new exon between 
exons 11 and 12, which started with an in-frame translational 
stop codon (Fig. 1 A). Importantly, mice homozygous for the 
ADAM17 ex allele (Fig, 1 A; Fig. S1 A) were viable. The   
usage of the new exon between exons 11 and 12 of the mouse 
ADAM17 gene was tested by RT-PCR as outlined in Fig. 1 B. 
Whereas in WT animals only a band of 380 bp was detected, 
heterozygous ADAM17WT/ex mice showed an additional band 
of 550 bp corresponding to the insertion of the new exon   
ADAM17 is the major endotoxin-stimulated TNF sheddase in 
myeloid cells in vivo and that ADAM17 is involved in the   
control of physiological bone remodeling, they did not clarify 
the role of ADAM17 in complex settings such as inflammation 
and cancer. Studies of ADAM17 have been complicated by the 
fact that it is not clear whether the protease and its substrates 
need to be expressed on the same cell or whether shedding in 
trans (i.e., the protease is expressed on one cell, the substrate on 
a different cell) is possible (Janes et al., 2005). Therefore, the 
choice of cre-transgenic mice for tissue-specific deletion of the 
ADAM17 gene in conditional mice is ambiguous.
In this paper, we developed a novel strategy to generate 
mice with barely detectable levels of ADAM17 in all tissues. 
The strategy is based on the generation of a new exon within 
the ADAM17 gene, which starts with an in-frame transla-
tional stop codon and which was flanked by splice donor/ 
acceptor sites, which slightly deviated from the canonical   
consensus sequence. This strategy has been named exon- 
induced translational stop (EXITS). Homozygous mice used 
the new exon for 95% of the ADAM17 mRNAs, resulting 
in a dramatic loss of ADAM17 protein in all cell types. Nev-
ertheless, homozygous ADAM17ex/ex mice were viable and 
Figure 1.  Targeted generation of 
ADAM17ex/ex mice. (A) Scheme for target-
ing the ADAM17 gene. Open arrowheads 
denote FLP recombinase sites, and LoxP 
sites are indicated by closed arrowheads. 
The altered allele contains an artificial exon 
starting with an in-frame translational 
stop codon placed downstream of exon 11. 
The artificial exon (E11a, yellow) containing 
the stop codon is flanked by noncanonical 
splice donor and acceptor sites (see Materi-
als and methods). The black bar indicates 
the hybridization probe used for Southern 
blotting. (B) mRNA from liver and brain 
was analyzed by RT-PCR. (C) ADAM17 and 
ADAM10 Western blots of skin and heart 
tissues. (D and E) Shedding of L-selectin 
from B cells (D) and TNF from spleen cells 
(E) was analyzed by FACS and ELISA,  
respectively. (F) Serum levels of sTNF-RII 
were measured by ELISA. Data in D–F are 
shown as mean values ± SD. (G) Formation 
of milk ducts in mice at the age of 12 wk. 
Representative pictures from four animals 
are shown. Bars, 500 µm.JEM VOL. 207, August 2, 2010  1619
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developing female animals (Sternlicht et al., 2005). As shown 
in Fig. 1 G, in contrast to WT mice, milk duct development   
was reduced in ADAM17ex/ex mice at 12 wk (Fig. 1 G, right), 
indicating  that  AR-induced  milk  duct  formation  required 
ADAM17-mediated cleavage of this EGF-R ligand.
Blockade of TNF has been shown to be beneficial for the 
treatment  of  patients  with  Crohn’s  disease  (van  Dullemen   
et al., 1995). Therefore, it was of interest to examine such a 
condition in ADAM17ex/ex animals. When WT and heterozy-
gous ADAM17WT/ex mice were treated with a mild regimen 
(2%) of DSS, they showed mild weight loss (Fig. 2 A) and 
minimal signs of inflammation upon endoscopy (Fig. 2 B). In 
contrast, homozygous ADAM17ex/ex animals exhibited severe 
weight loss and five of eight mice died. Colonoscopy revealed 
severe inflammation and ulcerations in these animals (Fig. 2 B) 
and an increase in endoscopic index of colitis severity (Fig. S3). 
ADAM17 protein was expressed in the crypts of the intestine 
of WT mice and was up-regulated upon DSS challenge but 
could not be detected in ADAM17ex/ex animals (Fig. 2 C). In 
ADAM17ex/ex animals, the crypt structure was completely lost 
sequence. In homozygous ADAM17ex/ex mice, 95% of the 
ADAM17 mRNAs contained the new exon. Consequently, 
almost no ADAM17 protein was detected in all tissues ana-
lyzed (Fig. 1 C; Fig. S1 B). These results indicated that we had 
generated viable mice with barely detectable ADAM17 pro-
tein levels in all tissues. ADAM17ex/ex mice were born at a fre-
quency  clearly  below  the  expected  Mendelian  distribution 
pattern (Table S1). Homozygous ADAM17ex/ex mice showed 
abnormalities of the eyes, skin, and heart, but not in the brain, 
body segmentation, or vascular development, indicating that 
ADAM17 is not crucial for developmental Notch or Notch 
ligand function in vivo (Fig. S2).
Generation of soluble L-selectin and TNF was completely 
abrogated in ADAM17ex/ex mice and levels of sTNF-RII were 
significantly reduced, indicating that shedding of ADAM17 
substrates was severely impaired (Fig. 1, D–F). ADAM17 has 
been implicated in the cleavage of membrane-bound ligands   
of the EGF-R (Sternlicht et al., 2005). Soluble, but not 
membrane-bound,  amphiregulin  (AR)  has  been  shown  to   
be sufficient and necessary for the formation of milk ducts in 
Figure 2.  ADAM17ex/ex mice are highly susceptible to DSS-induced colitis. (A) Body weight after the onset of treatment with DSS. Numbers  
of mice per group used are indicated. The experiment was performed three times. (B) Colonoscopy of untreated (top) and treated (bottom) mice.  
Representative pictures are shown. (C) DSS-treated (4 d) and untreated WT and ADAM17ex/ex mice were immunostained with anti-ADAM17 (magnifica-
tion, 100×). Bars, 100 µm. Representative macroscopic pictures of four mice per group are shown. (D) Hematoxylin and eosin (H&E), BrdU, anti– 
phosho-STAT3, and anti-cyclin D1 staining of colons from mice challenged for 10 d with DSS. Bars: (H&E) 200 µM; (BrdU, p-STAT3, and cyclin D1)  
100 µm. Representative microscopic images of three experiments (H&E and BrdU), two experiments (pSTAT3), and one experiment (cyclin D1) of  
ADAM17ex/ex, ADAM17WT/ex, and WT controls (five mice per group) are shown. (E) DSS colitis was induced and plasma FITC-dextran concentrations in  
ADAM17WT/WT (n = 7) and ADAM17ex/ex (n = 7) mice 4 h after FITC-dextran administration by oral gavage (60 mg/100 g of body weight) are shown.  
Data are shown as mean values ± SD. The experiment was performed twice with similar results.1620 ADAM17 in inflammation and regeneration | Chalaris et al.
proliferation in colon tissue sections was detected (Fig. 3 B). 
Gene expression analysis in the intestine of unchallenged 
mice revealed significant up-regulation of genes involved in 
immunity and defense as well as of genes playing a role in   
interferon-mediated immunity (Fig. 3 C and Fig. S4). These 
findings indicated that loss of ADAM17 activity, although it 
did not result in an overt inflammatory phenotype, led to a 
significant inflammatory gene expression signature, possibly 
resulting in sensitization toward inflammatory stimuli.
In DSS-treated animals we detected a strong increase in 
myeloperoxidase activity in ADAM17ex/ex animals (Fig. S5 A), 
which  is  considered  a  marker  for  activated  neutrophils 
(Breckwoldt et al., 2008). In colon organ cultures from DSS-
treated animals the inflammatory chemokines KC and MCP-1 
were elevated in ADAM17ex/ex mice. Interestingly, the anti-
inflammatory cytokine IL-10 and the IL-6–related cytokine 
IL-11 were also up-regulated in these animals (Fig. S5, B–E). 
Such an up-regulation of IL-10 and IL-11 was also seen in 
DSS-challenged mice with a deletion of STAT3 in intestinal 
epithelial cells (Bollrath et al., 2009). Consequently, an in-
crease of CD68-positive mononuclear cells and CD3-positive   
T cells in intestinal tissue sections of DSS-treated ADAM17ex/ex 
animals was detected (Fig. S5, F and G). The cytokines   
TNF, IL-21, IL-12, and IL-17 were not significantly up- 
regulated (unpublished data).
after day 10 (Fig. 2 D). Interestingly, a similar damage was seen 
in mice with targeted disruption of STAT3 in epithelial cells of 
the intestine. These mice, upon treatment with azoxymethane/ 
DSS, showed destruction of the colon architecture (Bollrath   
et al., 2009; Grivennikov et al., 2009; Pickert et al., 2009). 
Stimulation of the EGF-R was shown to lead to activation and 
phosphorylation of STAT3 (Itoh et al., 2006). We therefore 
hypothesized that the regenerative response of colonic epithe-
lial cells of ADAM17ex/ex mice was compromised.
DSS is toxic to gut epithelial cells of the basal crypts and 
affects the integrity of the mucosal barrier (Wirtz et al., 2007). 
Colon sections of WT and ADAM17WT/ex mice exhibited 
proliferating nuclei throughout the crypts of the gut (Fig. 2 D). 
No such staining was seen in ADAM17ex/ex mice. In WT and 
ADAM17WT/ex mice, but not in ADAM17ex/ex mice, phos-
phorylated  STAT3  and  cyclin  D1  were  readily  detectable 
(Fig. 2 D). These results indicated that in ADAM17ex/ex mice 
the proliferative response of intestinal epithelial cells to DSS 
was blocked, presumably as a result of the inability to activate 
EGF-R–mediated STAT3 phosphorylation (Itoh et al., 2006). 
Importantly, upon DSS challenge, the intestinal barrier be-
came highly permeable for FITC-dextran in ADAM17ex/ex 
mice (Fig. 2 E).
Surprisingly, in unchallenged ADAM17ex/ex mice the   
colon mucosa was regularly arranged (Fig. 3 A) and unaltered 
Figure 3.  Intestinal architecture, epithelial proliferation, and gene expression in unchallenged ADAM17ex/ex mice. (A) H&E staining of paraffin-
embedded colon tissue from unchallenged ADAM17ex/ex mice. Bar, 100 µM. Representative microscopic pictures of eight ADAM17ex/ex mice are shown.  
(B) ADAM17ex/ex (n = 3) and WT (n = 3) mice were injected intraperitoneally with BrdU and stained for BrdU in the distal colon. The arrowheads indicate 
BrdU-positive nuclei. Bars, 100 µm. The experiment was performed three times with three animals per group. (C) Pathway analysis of microarray data 
from colon tissue of WT (n = 3) and ADAM17ex/ex (n = 3) mice. Regulated genes, which are significantly enriched or depleted during biological processes, 
are displayed. The bar represents the log(p) of the probability of the enrichment or depletion occurring by chance. Processes that are associated with 
down-regulated transcripts are shown on the left, and those associated with up-regulated transcripts are shown on the right. The numbers in the bars 
represent the number of observed regulated transcripts in the category.JEM VOL. 207, August 2, 2010  1621
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was completely absent in ADAM17ex/ex mice. This finding is 
consistent with a study showing that mice lacking TGF- have 
an increased susceptibility to DSS-induced colitis (Egger et al., 
1997) and that TGF-–overexpressing mice were less suscepti-
ble to DSS-induced colitis (Egger et al., 1998). The EGF-R can 
The  inflammatory  response  seen  in  homozygous   
ADAM17ex/ex mice was not the result of an intrinsic activation 
of the immune system in these animals, as demonstrated in a   
T cell transfer colitis model where T cells from WT or homo-
zygous ADAM17ex/ex mice were transferred into rag/ ani-
mals (Powrie et al., 1994; Atreya et al., 2000). Importantly, no 
significant difference in colitis development was detected when 
comparing animals transplanted with WT or ADAM17ex/ex  
T cells (unpublished data).
We hypothesized that the failure of intestinal epithelial cells 
to proliferate was caused by the fact that ADAM17ex/ex mice 
could not cleave and thereby systemically activate ligands of 
the EGF-R (Berasain et al., 2009). As shown in Fig. 4 A, after 
DSS challenge, higher levels of cell surface–expressed TGF- 
were detected in ADAM17ex/ex mice as compared with WT 
animals. We therefore asked whether injection of recombinant 
TGF- would restore proliferation of intestinal epithelial cells. 
As shown in Fig. 4 B, treatment of ADAM17ex/ex mice with 
this EGF-R ligand induced intestinal epithelial cell prolifera-
tion to a degree, which clearly surpassed the proliferation seen 
in WT animals. Concomitantly, phosphorylation of STAT3 
was induced in TGF-–treated mice. Interestingly, WT and 
ADAM17ex/ex mice upon daily injection of EGF-R ligand lost 
less weight than PBS-injected animals (Fig. 4 C). These results 
demonstrated that in ADAM17ex/ex mice signaling downstream 
of the EGF-R was intact and that ectopic stimulation of this 
pathway compensated for the loss of proliferation caused by 
the deficiency of ADAM17.
Although the cre/loxP technology (Kühn et al., 1995) has 
been helpful in the analysis of gene defects in animals when   
total deletion of the gene of interest was lethal, there are limita-
tions to this method. In cases when the expression profile and 
the activity of the gene of interest is complex or when it is not 
known which cell type is responsible for the synthesis and se-
cretion of a soluble protein, it can be difficult to choose the 
appropriate transgenic cre mouse. In the case of ADAM17, it 
is not clear whether the protease exclusively cleaves its targets 
in cis or whether shedding in trans is possible (Janes et al., 
2005). Furthermore, many functions of ADAM17 remained 
unknown as a result of embryonic lethality caused by ADAM17 
gene deletion (Peschon et al., 1998). The phenotypes described 
in this paper are based on the development of a novel knockin 
targeting strategy, leading to an almost complete absence of 
functional ADAM17 protein as the result of a premature trans-
lational stop codon encoded by the artificially introduced exon. 
Our approach can be adapted to other genes as we showed in 
the case of the human CNTF gene (unpublished data) and will 
therefore be generally applicable.
Our experiments showed that for all substrates tested,   
shedding in ADAM17ex/ex animals was severely compromised. 
Physiological  proliferation  in  the  intestine  of  ADAM17ex/ex 
mice was normal, indicating that ADAM17 activation was not 
needed. In contrast, formation of milk ducts in 12-wk-old mice 
was abrogated as a result of the lack of AR processing. During 
the regenerative response i.e., after DSS treatment, the STAT3-
mediated proliferative response of the intestinal epithelial cells 
Figure 4.  Cellular accumulation of TGF- and compensatory prolif-
eration induced by recombinant TGF-. (A) Colonic tissue sections from 
unchallenged and challenged WT and ADAM17ex/ex mice (4  d, 2% DSS) 
were stained for TGF-. Representative microscopic pictures of three mice 
per group are shown. Bars, 100 µm. (B) Colitis was induced in WT (n = 5) 
and ADAM17ex/ex (n = 9) mice with 2% DSS for 10 d. ADAM17ex/ex mice were 
injected daily with recombinant TGF- (15 µg/mouse; n = 5) or with PBS  
(n = 4). Representative microscopic images of one experiment with five WT 
mice, four ADAM17ex/ex mice treated with PBS, and five ADAM17ex/ex mice 
treated with TGF- are shown. Bars, 100 µm. The experiment was  
performed twice with similar results. (C) Colitis was induced in WT and 
ADAM17ex/ex mice with 2% DSS and the animals were injected daily with 
the EGF-R ligand EGF (15 µg/mouse; WT, n = 3; ADAM17ex/ex mice, n = 8)  
or with PBS, (WT, n = 8; ADAM17ex/ex mice, n = 9) and body weight was 
recorded. Data were pooled from two independent experiments.1622 ADAM17 in inflammation and regeneration | Chalaris et al.
following sources: TGF- (PeproTech); LPS, FITC-dextran, and my-
eloperoxidase  (Sigma-Aldrich);  PMA  (EMD);  anti-CD3,  anti-CD28, 
anti–CD4-FITC, anti–B220-FITC, and anti–L-selectin–PE (BD); anti– 
phospho-STAT3 and anti–cyclin-D1 (Cell Signaling Technology); and horse-
radish peroxidase–coupled anti–goat antibody (Thermo Fisher Scientific). The 
anti-ADAM10 and anti-ADAM17 antisera were a gift from S. Weber (Institute 
of Biochemistry, Christian-Albrechts-University, Kiel, Germany).
Generation of ADAM17ex/ex knockin mice. We created hypomorphic and 
conditional knockout mice of ADAM17. The ADAM17 gene is composed of 
18 exons. We designed the targeting vector in a way that exon 11, which en-
codes the catalytic zinc-binding domain, is flanked by two loxP sites and the 
FTR-flanked neo cassette. A cryptic acceptor splice site within the intron 11 of 
ADAM17 was predicted using the NetGene2 program. Hypomorphic expres-
sion of ADAM17 was achieved by inserting a loxP site together with a cryptic 
noncanonical donor splice site (GAG-GTAATT instead of the canonical se-
quence A/CAG-GTAAGT, where the hyphen denotes the exon-intron bor-
der) downstream of the cryptic acceptor splice site into intron 11 and thereby 
generating an additional, artificial, exon 11a (Fig. 1 A). Alternative splicing/use 
of the artificial exon 11a led to premature disruption of ADAM17 protein trans-
lation as a result of the in-frame stop codon TAG in exon 11a. If needed, dele-
tion of exon 11 could be achieved by tissue-specific cre recombinase–mediated 
deletion of exon 11 of the ADAM17 gene. The ADAM17 targeting plasmid was 
assembled in pBR322 using standard cloning techniques. In brief, the 5ADAM17 
small homology was followed by the first loxP site, the FTR-neomycin-FTR 
cassette, partial intron 10, exon 11, and the first half of intron 12 (including the 
cryptic but canonical splice acceptor site), the second loxP site, an artificial non-
canonical splice donor site, and the 3ADAM17 large homology. Mouse 
ADAM17 is located on the minus strand of chromosome 12 from 21,329,378 to 
21,379,454 bp (from VEGA annotation of National Center for Biotechnology 
Information Build 37). To simplify annotation of the ADAM17 sequences sub-
cloned into our targeting plasmid, we defined the adenine base from the start 
codon ATG of the ADAM17 gene as position 1. The subcloned fragments were: 
5ADAM17 small homology from position 35,826 to 36,574, partial intron 10, 
exon 11, and the first half of intron 12 from position 36,575 to 37,976 and 
3ADAM17 large homology from position 37,977 to 43,640. The ADAM17 
gene fragments were subcloned into pBR322 from a genomic lambda clone. 
The resulting plasmid was named pBR322-ADAM17-targeting. 129 SvEv ES 
cells were transfected with the ADAM17 targeting vector to obtain clones with 
homologous recombination. Targeted embryonic stem cells were injected 
into C57BL/6 blastocysts to produce chimeras, and germline-transmitted   
ADAM17exneo/+ mice were obtained by mating chimeras with C57BL/6 mice 
(InGenious Targeting Laboratory). Because ADAM17exneo/exneo mice were not 
viable, presumably because of the presence of the neomycin gene cassette, we 
deleted this cassette by crossing with ACTB:FLPe mice expressing FLP recom-
binase under the control of the -actin promoter (Rodríguez et al., 2000). These 
mice were obtained from F. Stewart (BioInnovation Zentrum, Technical Uni-
versity Dresden, Dresden, Germany). Homozygous ADAM17ex/ex mice were 
viable but showed drastically reduced ADAM17 protein levels. To verify 
whether this strategy may be generally applicable, we introduced a DNA se-
quence containing the same noncanonical acceptor splice site and donor splice 
site into the single intron of the human CNTF gene. This approach led to the 
same result seen for the mouse ADAM17 gene. The introduced exon was only 
partly used in transfected HepG2 cells, leading to inefficient translation of the 
CNTF protein. We therefore concluded that the EXITS strategy should be ap-
plicable to other genes to generate hypomorphic phenotypes.
Southern blotting. 10 µg of genomic DNA was digested by HindIII, sepa-
rated on 0.8% agarose gels, and transferred to a nylon membrane, which was 
hybridized at 65°C overnight with the -32P-dATP–labeled probe as indi-
cated in Fig. 1 A. The membrane was washed at 65°C and signals were de-
tected by phosphoimaging.
RT-PCR. RNA was isolated from different organs and 2 µg was reverse 
transcribed into cDNA using Reverse Aid M-MuLV reverse transcription 
be stimulated by its cognate ligands in a paracrine and in a sys-
temic fashion (Rodland et al., 2008). Thus, ADAM17ex/ex mice 
will be a good model to study the differences between EGF-R 
signaling via membrane-bound and soluble ligands.
The activation mechanisms of ADAM17 are not fully under-
stood. In contrast to matrix metalloproteases, which are activated 
by the removal of the prodomain, ADAM17 additionally needs 
to be activated by intra- or extracellular signaling (Murphy, 2008). 
Recently, we showed that induction of apoptosis in neutrophils 
led to selective activation of ADAM17 and subsequent shedding 
of the IL-6R (Chalaris et al., 2007) and that this mechanism 
might represent a gauge to measure the extent of damage en-
countered by neutrophilic cells. In view of the pleiotropic activi-
ties governed by ADAM17, it will be interesting to study how 
the activity of this protease is regulated under stress conditions.
The intestine of unchallenged ADAM17ex/ex mice appeared 
normal but failed to respond adequately to the tissue damage by 
DSS, although we detected an up-regulation of inflammatory 
genes. These results show that ADAM17 plays a role in the co-
ordination of reactions toward stress caused by wounding. The 
intestinal epithelium acts as an intrinsic barrier against microbial 
invaders. Our data show that lack of regeneration and failure to 
maintain the barrier function of the intestine act dominantly over 
the reduced activity of the immune system as a result of impaired 
shedding of, for example, TNF, caused by diminished ADAM17 
activity. As a consequence, ADAM17ex/ex mice were more sus-
ceptible in a model of inflammatory bowel disease.
Because ADAM17 is the main sheddase for TNF and sev-
eral ligands of the EGF-R (Peschon et al., 1998), this protease 
has been considered to be a target of therapeutic drugs for the 
treatment of inflammatory diseases (Moss et al., 2008) and can-
cer (Kenny, 2007). In view of the role ADAM17 played in the 
coordination of the regeneration response in the gut, it now 
becomes clear that inhibition of ADAM17 might have severe 
side effects, such as lack of tissue regeneration. In contrast, many   
tumors largely depend on the activity of the EGF-R, which 
can be efficiently blocked by inhibition of ADAM17. In this 
respect, our mouse model is well suited to evaluate the conse-
quences of ADAM17 deficiency in vivo. It is noteworthy that 
our strategy is based on the presence of some residual ADAM17 
activity, which is also likely to be present upon pharmacologi-
cal inhibition of this protease.
In summary, we presented the novel EXITS method for 
gene targeting, which will be applicable to other genes. Using 
this technique, viable mice with greatly diminished ADAM17 
activity in all tissues were generated. Models of inflammatory 
bowel disease showed that these mice were highly susceptible 
to intestinal damage by DSS and point to a function of ADAM17 
in the coordination of pro- and antiinflammatory activities in 
response to body stress and damage.
MATERIALS AND METHODS
Reagents and antibodies. Reagents were purchased from Carl Roth unless 
otherwise specified. Restriction enzymes, molecular weight markers, Taq-
polymerase, and reverse transcription were obtained from Fermentas. Cell 
culture media, trypsin, FCS, L-glutamine, and penicillin/streptomycin were 
obtained from PAA Laboratories. All other reagents were obtained from the JEM VOL. 207, August 2, 2010  1623
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light–dark cycle under standard conditions and were provided with food and 
water ad libitum. Procedures involving animals and their care were con-
ducted in conformity with national and international laws and policies. Blood 
was drawn from the mice by cardiac puncture under general anesthesia.
Histological  examination  and  immunohistochemistry. Tissues were 
fixed in 4% formalin or 4% PFA (colon tissue) and embedded in paraffin. Sec-
tions of 5 µM were stained with H&E using standard procedures. pSTAT3, 
ADAM17,  and  cyclin  D1  staining  were  performed  using  an  anti–mouse 
pSTAT3 mAb (1:3,000), an anti–rabbit cyclin D1 mAb (1:100), or an anti–
rabbit ADAM17 (1:100) diluted in sample diluents (Dako), and the signal was 
amplified using the Tyramide Signal Amplification kit (PerkinElmer) and de-
veloped with AEC substrate (Dako). To visualize BrdU incorporation, sec-
tions were stained with a 1:500 dilution of mouse anti-BrdU mAb (Roche) 
overnight. Then the sections were incubated for 1 h with biotinylated anti–
mouse secondary antibody (1:50; Dako) and developed with AEC substrate. 
Counterstaining was performed with Shadon Gill III hematoxylin (Thermo 
Fisher Scientific). The TGF- staining was performed using a goat anti–mouse 
TGF- mAb (1:50; R&D Systems). Staining was visualized after incubation 
with AEC substrate and counterstaining was performed with Gill III hema-
toxylin. For immunofluorescence staining, cryosections were fixed in ice-cold 
acetone for 10 min, followed by sequential incubation with blocking reagent 
(Dako) to eliminate unspecific background staining. Slides were then incu-
bated for 1 h at room temperature with primary antibodies against CD3 (1:50; 
Abcam) and CD68 (1:100; Santa Cruz Biotechnology, Inc.). After three times 
washing with PBS, slides were incubated for 45 min at room temperature with 
Cy3- or FITC-labeled secondary antibodies (Jackson ImmunoResearch Labo-
ratories). Before examination, nuclei were counterstained with DAPI.
Microarray analysis. Total RNA was extracted and processed as previously   
described (Häsler et al., 2009) and hybridized to a mouse gene 1.0 ST array   
(Affymetrix) according to the manufacturer’s protocol. Data were normalized   
using RMA (AGCC; Affymetrix), and signals that were not stronger than the 
95th percentile of all intron probes on the array were excluded from further anal-
ysis. Experimental and analytical part of the microarray analysis was performed ac-
cording to the MIAME standards. The fold change was calculated based on the 
ratios of the two medians (WT vs. EX). Inclusion criteria for the genes in the 
Gene Ontology analysis and the cluster were a fold change >+2 or <2, with a 
rank-sum difference ≥ 9. Only characterized genes (no ESTs and no predicted 
genes) were included. Gene Ontology analysis was performed as previously pub-
lished (Tavazoie et al., 1999) by comparing regulated genes versus detected genes. 
Biological processes associated with regulated transcripts were retrieved from the 
Gene Ontology Consortium (www.geneontology.org). The hierarchical cluster 
was generated based on regulated genes using the correlation as the similarity 
measure and UPGMA (unweighted mean) as the clustering method (Spotfire 
Decision Site 9.1.1). The microarray data can be accessed at http://www.ncbi 
.nlm.nih.gov/geo/ under the accession no. GSE21691.
Statistical analysis. All parametric data are presented as the means ± SD. 
Data from two groups were analyzed for significance using the Student’s   
t test. Differences were considered to be statistically significant if P ≤ 0.05.
Online supplemental material. Fig. S1 shows Southern blots and Western 
blots of mice demonstrating homologous recombination of the ADAM17   
ex allele and lack of ADAM17 protein expression in brain, liver, and spleen. 
Fig. S2 shows the open eye, skin, heart, and brain phenotype of ADAM17ex/ex 
mice. Fig. S3 demonstrates the endoscopic score and disease activity of mice 
after DSS treatment. Fig. S4 depicts a gene expression analysis in the intestine 
of WT and ADAM17ex/ex mice. Fig. S5 demonstrates increased intestinal in-
flammation in DSS-treated ADAM17ex/ex mice. Table S1 demonstrates seg-
regation of offspring from ADAM17ex/ex mice. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20092366/DC1.
We thank Manfred Blessing, Karl-Joseph Kallen, Jacques Peschon, and Jürgen 
Müllberg for their help during the initial phase of the project. The contribution 
(Fermentas). ADAM17 transcripts were subsequently amplified by PCR 
using the following primer pair: 3exon 12 (5-TAATACCCGGGTCA-
CACTCC-3) and 5exon 10 (5-CTTATTACAACCCAACTGTG-3).
Induction of colitis and determination of clinical scores. Colitis was in-
duced by administration of 2% DSS (mol wt, 40,000; TdB Consultancy) in the 
drinking water for 5 d followed by 5 d of regular drinking water. A high- 
resolution mouse video endoscopic system was used (HOPKINS Optik 64019BA; 
KARL STOLZ AIDA VET). Mouse endoscopic index of colitis severity scores 
(MEICS) and disease activity index (DAI) were obtained as previously described 
(Fantini et al., 2006). In some experiments, mice were given daily doses (15 µg/
mouse) of recombinant TGF-, EGF, or PBS by intraperitoneal injection.
FITC-dextran and BrdU administration. Intestinal permeability was as-
sessed by administration of nonmetabolized FITC-dextran 4000 (Sigma- 
Aldrich). FITC-dextran was administered by oral gavage (60 mg/100 g of 
body weight) 4 h before killing. Whole blood was obtained by cardiac punc-
ture and serum was obtained by centrifugation at 5,000 rpm for 15 min.   
Dilutions of FITC-dextran 4000 in PBS were used as a standard curve, and 
absorption of 100 µl of serum or standard was measured at 488 nm. To study 
proliferation of epithelial cells, 50 mg BrdU/kg of body weight (EMD) was 
injected intraperitoneally 2 h before sacrifice.
Colon organ culture and ELISA. A segment of the distal colon was re-
moved, cut open longitudinally, and washed in PBS containing penicillin 
and streptomycin. The colon was then further cut into segments of 1 cm2, 
placed, and incubated in 6-well flat-bottom culture plates containing 2 ml of 
fresh DME supplemented with penicillin and streptomycin at 37°C for 24h. 
Culture  supernatants  were  then  harvested  and  assayed  for  KC,  MCP-1,   
IL-10, IL-11, IL-12, IL-17, IL-21, and TNF levels by ELISA assays (R&D 
Systems) according to the manufacturer’s protocols.
Myeloperoxidase  (MPO)  activity  measurement. MPO activity was 
measured in colon tissue taken from the distal colon. After freezing in liquid 
nitrogen, equal amounts of tissue samples (30 µl of buffer/mg of colon tissue) 
were homogenized in MPO buffer (0.05 KPO4 and 0.5% hexadecyl tri-
methyl ammonium bromide), incubated at 60°C for 2 h, and centrifuged for 
5 min at 10,000 rpm. 10 µl of the supernatant was mixed with 50 µl peroxi-
dase substrate (BM blue POD; Roche). After 10–20 min, the reaction was 
stopped by 50 µl H2SO4 and absorbance was read at 450 nm.
Western blotting. To monitor protein expression, tissue samples were ho-
mogenized in lysis buffer (150 mM NaCl, 2 mM EDTA, 50 mM tris-HCl, pH 
7.4, 1% Triton X-100, and 1% NP-40) containing complete protease inhibitor 
(Roche), and equivalent amounts of homogenate were used for SDS-PAGE. 
Proteins were transferred to PVDF membranes (GE Healthcare) incubated 
with primary and secondary antibodies and visualized by chemiluminescence.
Flow cytometric analysis. 107 mouse splenocytes were stimulated with 100 nM   
PMA for 2 h, 1 µg/ml LPS for 24 h, or 5 µg/ml anti-CD3 and 1 µg/ml anti-
CD28 for 24 h and subsequently washed twice with FACS buffer (PBS, 1% 
BSA, and 0.01% NaN3). To block Fc receptors, the cell suspension was incu-
bated with mouse Fc block CD16/32 mAb (BD) for 10 min and further stained 
with fluorescence-coupled antibodies against the B cell marker B220, T cell 
marker CD4, or L-selectin. Cells were washed with 500 µl FACS buffer and an-
alyzed by FACS (FACS-Canto; BD). Data were acquired from 50,000 gated 
events per sample and further analyzed with the FACS Canto Diva Software.
Brain histology. After perfusion with 6% glutaraldehyde in phosphate buf-
fer, brains from WT and ADAM17ex/ex mice were serially sectioned at 100 µm 
on a vibratome (1200 S; Leica) and stained with 0.1% methylene blue.
Animal treatment. All experiments were performed in accordance with 
the animal care guidelines of the University of Kiel (acceptance no.: V 742–
72 241.121-3 (20–2/04) and (76–7/00)). Mice were maintained in a 12-h 1624 ADAM17 in inflammation and regeneration | Chalaris et al.
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